These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 29264938)

  • 1. A concise review of BCL-2 inhibition in acute myeloid leukemia.
    Yogarajah M; Stone RM
    Expert Rev Hematol; 2018 Feb; 11(2):145-154. PubMed ID: 29264938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML.
    Wei AH; Tiong IS
    Blood; 2017 Dec; 130(23):2469-2474. PubMed ID: 29051180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recently approved therapies in acute myeloid leukemia: A complex treatment landscape.
    Talati C; Sweet K
    Leuk Res; 2018 Oct; 73():58-66. PubMed ID: 30223250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venetoclax-based therapies for acute myeloid leukemia.
    Guerra VA; DiNardo C; Konopleva M
    Best Pract Res Clin Haematol; 2019 Jun; 32(2):145-153. PubMed ID: 31203996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New drugs creating new challenges in acute myeloid leukemia.
    Tiong IS; Wei AH
    Genes Chromosomes Cancer; 2019 Dec; 58(12):903-914. PubMed ID: 30861214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Which new agents will be incorporated into frontline therapy in acute myeloid leukemia?
    Stone RM
    Best Pract Res Clin Haematol; 2017 Dec; 30(4):312-316. PubMed ID: 29156201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shutting Down Acute Myeloid Leukemia and Myelodysplastic Syndrome with BCL-2 Family Protein Inhibition.
    Sharma P; Pollyea DA
    Curr Hematol Malig Rep; 2018 Aug; 13(4):256-264. PubMed ID: 29982865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First new drug approval for AML in 15 years.
    Sheridan C
    Nat Biotechnol; 2017 Aug; 35(8):696-698. PubMed ID: 28787411
    [No Abstract]   [Full Text] [Related]  

  • 9. New agents: great expectations not realized.
    Lancet JE
    Best Pract Res Clin Haematol; 2013 Sep; 26(3):269-74. PubMed ID: 24309529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What to use to treat AML: the role of emerging therapies.
    Thol F
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):16-23. PubMed ID: 34889359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
    Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
    Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted Therapeutic Approach Based on Understanding of Aberrant Molecular Pathways Leading to Leukemic Proliferation in Patients with Acute Myeloid Leukemia.
    Song MK; Park BB; Uhm JE
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
    Luskin MR; DeAngelo DJ
    Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myelodysplastic syndromes and acute myeloid leukemias in the elderly.
    Mueller BU; Seipel K; Pabst T
    Eur J Intern Med; 2018 Dec; 58():28-32. PubMed ID: 30527920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemtuzumab Ozogamicin (GO) Inclusion to Induction Chemotherapy Eliminates Leukemic Initiating Cells and Significantly Improves Survival in Mouse Models of Acute Myeloid Leukemia.
    Zhang CC; Yan Z; Pascual B; Jackson-Fisher A; Huang DS; Zong Q; Elliott M; Fan C; Huser N; Lee J; Sung M; Sapra P
    Neoplasia; 2018 Jan; 20(1):1-11. PubMed ID: 29172076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
    Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
    J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How I treat acute myeloid leukemia in the era of new drugs.
    DiNardo CD; Wei AH
    Blood; 2020 Jan; 135(2):85-96. PubMed ID: 31765470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [What is recommended in the treatment of acute myeloid leukemia?].
    Thol F
    Internist (Berl); 2019 Dec; 60(12):1240-1250. PubMed ID: 31690995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Gemtuzumab ozogamicin for treatment of acute myeloid leukemia].
    Brotelle T; Lemal R; Moluçon-Chabrot C; Bay JO; Delaunay J; Guièze R
    Bull Cancer; 2014 Feb; 101(2):211-8. PubMed ID: 24557850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ＜Editors' Choice＞ How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement.
    Naoe T
    Nagoya J Med Sci; 2020 May; 82(2):151-160. PubMed ID: 32581396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.